一个关于MYBPC3基因突变在多变性心肌病的更新
Bogdan-Sorin Tudurachi1,2, Alexandra Zăvoi2, Andreea Leonte2
1Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 University Street, 700115 Iasi, Romania.
International journal of molecular sciences
|July 14, 2023
概括
增高性心肌病变 (HCM) 是一种遗传性心脏病. MYBPC3基因突变是主要原因,影响疾病严重程度和患者的结果.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传疾病 遗传疾病
背景情况:
- 增高性心肌病变 (HCM) 是最常见的遗传性心脏病,通常是随着自体主导遗传.
- 编码心脏肌酸结合蛋白C (cMyBP-C) 的MYBPC3基因的突变是大多数HCM病例的原因.
- HCM的临床表现复杂,受遗传突变,环境因素和蛋白质/转录质量控制系统的影响.
研究的目的:
- 审查MYBPC3突变在高伤心肌病 (HCM) 中的作用.
- 探索MYBPC3突变特征如何影响疾病发病和临床后果.
- 了解MYBPC3作为HCM的预后决定因素的作用.
主要方法:
- 文献综述侧重于MYBPC3基因突变在HCM.
- 分析检查突变类型与临床表现之间的关系的研究.
- 综合有关遗传因素和蛋白质/转录质量控制在HCM病原体的信息.
主要成果:
- MYBPC3突变是HCM的主要遗传原因,已经确定了各种突变类型 (截断,插入/删除,框架转移,误解).
- 泛素蛋白酶体系统的干扰和无意义介导的RNA衰变与HCM的发展有关.
- 特定的MYBPC3突变与各种临床结果相关,从无症状疾病到突然心脏死亡.
结论:
- MYBPC3突变是HCM表型和预后的关键决定因素.
- 虽然MYBPC3突变解释了HCM的很大一部分,但临床变异的全谱需要进一步调查.
- 了解MYBPC3突变特征对于预测HCM进展和患者结果至关重要.
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
01:25Cardiomyopathy I: Introduction and Classification
19
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
19
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12